journal article·2019-07-23Open access

Photoablation of Human Vitreous Opacities by Light-Induced Vapor Nanobubbles

Félix Sauvage, Juan C. Fraire, Katrien Remaut, J. Sebag, Karen Peynshaert, Michael Harrington, Frans J. Van de Velde, Ranhua Xiong, Marie-José Tassignon, Toon Brans, Kevin Braeckmans, Stefaan C. De Smedt

ACS Nano· Volume 13· Issue 7

Abstract

Myopia, diabetes, and aging are the main causes of progressive vitreous collagen aggregation, resulting in vitreous opacities, which can significantly disturb vision. As vitreous opacities, which induce the visual phenomenon of "floaters", are accessible with nanomaterials and light, we propose a nanotechnology-based approach to locally ablate them with highly reduced light energy compared to the more traditional YAG laser therapy. Our strategy relies on the plasmon properties of gold nanoparticles that generate vapor nanobubbles upon pulsed-laser illumination whose mechanical force can ablate vitreous opacities. We designed gold nanoparticles coated with hyaluronic acid (HA), which have excellent diffusional mobility in human vitreous, an essential requirement to reach the vitreous opacities. In addition, we found that HA-coated gold nanoparticles can accumulate extensively on human vitreous opacities that were obtained by vitrectomy from patients with vision-degrading myodesopsia. When subsequently applying nanosecond laser pulses, the collagen aggregates were efficiently destroyed with ∼1000 times less light energy than typically used in YAG laser therapy. This low-energy "floater-specific destruction", which is due to the accumulation of the small gold nanoparticles on the opacities, is attractive, as it may be safer to the surrounding ocular tissues while at the same time being easier and faster to apply compared to YAG laser therapy, where the opacities need to be ablated piece by piece by a tightly focused laser beam. Gold nanoparticle-assisted photoablation may therefore provide a safer, faster, and more reliable destruction of vitreous opacities in the treatment of ophthalmologic diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Retinal and Macular Surgery · Vascular Malformations Diagnosis and Treatment · Intraocular Surgery and Lenses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Laboratory of General Biochemistry & Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, Ghent 9000, Belgium

VMR Institute for Vitreous Macula Retina, Huntington Beach, California 92647, United States

Doheny Eye Institute/UCLA, Los Angeles, California 90033, United States

Huntington Medical Research Institutes, Pasadena, California 91105, United States

Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts 02114, United States

Department of Ophthalmology, Antwerp University Hospital, University of Antwerp, Antwerp 2020, Belgium

Funding

Universiteit Gent · Fonds Wetenschappelijk Onderzoek · Bijzonder Onderzoeksfonds · H2020 European Research Council

References (66)

Show source-provided references
1. 10.4161/pri.2.3.748810.4161/pri.2.3.7488 ↗
2. 10.1007/BF0216033710.1007/BF02160337 ↗
3. 10.1016/j.ajo.2011.01.02610.1016/j.ajo.2011.01.026 ↗
4. 10.1016/j.ajo.2011.02.01510.1016/j.ajo.2011.02.015 ↗
5. 10.1016/j.ajo.2011.09.00310.1016/j.ajo.2011.09.003 ↗
6. 10.1097/IAE.000000000000006510.1097/IAE.0000000000000065 ↗
7. 10.1016/j.oret.2018.03.01110.1016/j.oret.2018.03.011 ↗
8. 10.1016/j.survophthal.2015.11.00810.1016/j.survophthal.2015.11.008 ↗
9. 10.1007/s12013-013-9706-510.1007/s12013-013-9706-5 ↗
10. Procedure Guide: Vitreous Opacities - Ellex https://www.ellex.com/resources/procedure-guide-vitreous-opacities/ (accessed Nov 14, 2018).
11. 10.1038/sj.eye.670002610.1038/sj.eye.6700026 ↗
12. 10.1001/jamaophthalmol.2017.238810.1001/jamaophthalmol.2017.2388 ↗
13. 10.1136/bjophthalmol-2016-30900510.1136/bjophthalmol-2016-309005 ↗
14. 10.1016/j.ajo.2014.10.00610.1016/j.ajo.2014.10.006 ↗
15. 10.3928/23258160-20181101-2110.3928/23258160-20181101-21 ↗
16. 10.1136/bjo.77.8.48510.1136/bjo.77.8.485 ↗
17. Vandorselaer T. · Bull. Soc. Belge Ophtalmol. · 2001 · 15
18. 10.1039/C1CS15184C10.1039/C1CS15184C ↗
19. 10.1021/cr068028210.1021/cr0680282 ↗
20. 10.1021/nn304524310.1021/nn3045243 ↗
21. Sebag J. · 201410.1007/978-1-4939-1086-1 ↗
22. 10.1002/cyto.a.2226410.1002/cyto.a.22264 ↗
23. 10.1016/j.jconrel.2013.01.01810.1016/j.jconrel.2013.01.018 ↗
24. 10.1016/j.bpj.2015.10.00210.1016/j.bpj.2015.10.002 ↗
25. 10.2217/nnm.12.20210.2217/nnm.12.202 ↗
26. 10.1167/iovs.05-016510.1167/iovs.05-0165 ↗
27. 10.1016/j.ejps.2017.02.02710.1016/j.ejps.2017.02.027 ↗
28. 10.1021/acs.jpcc.7b0185410.1021/acs.jpcc.7b01854 ↗
29. 10.1364/OE.17.00253810.1364/OE.17.002538 ↗
30. 10.2217/17435889.2.2.24110.2217/17435889.2.2.241 ↗
31. 10.1021/jp312370910.1021/jp3123709 ↗
32. 10.1001/archopht.1991.0108007007803910.1001/archopht.1991.01080070078039 ↗
33. 10.1016/j.jconrel.2015.01.03010.1016/j.jconrel.2015.01.030 ↗
34. Asakura A. · Nippon Ganka Gakkai Zasshi · 1985 · 89 · 179
35. 10.1038/eye.1992.12010.1038/eye.1992.120 ↗
36. 10.1096/fasebj.6.9.161228710.1096/fasebj.6.9.1612287 ↗
37. 10.1246/cl.2008.83410.1246/cl.2008.834 ↗
38. 10.1177/26.8.69040710.1177/26.8.690407 ↗
39. Sebag J. · Invest. Ophthalmol. Vis. Sci. · 1989 · 30 · 1867
40. 10.1088/0957-4484/19/35/35570210.1088/0957-4484/19/35/355702 ↗
41. 10.1016/j.ijheatmasstransfer.2008.08.01010.1016/j.ijheatmasstransfer.2008.08.010 ↗
42. Riggins J. · Ophthalmic Surg. Lasers Imaging Retina · 1983 · 14 · 67510.3928/1542-8877-19830801-10 ↗
43. 10.1002/wnan.6510.1002/wnan.65 ↗
44. 10.1088/0957-4484/20/50/50510110.1088/0957-4484/20/50/505101 ↗
45. 10.1097/IAE.0b013e3180dc936010.1097/IAE.0b013e3180dc9360 ↗
46. 10.1002/med.2150910.1002/med.21509 ↗
47. 10.1021/acs.molpharmaceut.5b0084910.1021/acs.molpharmaceut.5b00849 ↗
48. 10.1056/NEJMcibr181333410.1056/NEJMcibr1813334 ↗
49. 10.1039/df951110005510.1039/df9511100055 ↗
50. 10.1021/ac070208410.1021/ac0702084 ↗
51. 10.1016/S0022-4073(01)00019-X10.1016/S0022-4073(01)00019-X ↗
52. Bohren C. F. · 1983
53. 10.1103/PhysRevE.58.393110.1103/PhysRevE.58.3931 ↗
54. Palik E. D. · 1991
55. 10.1364/OE.20.02297610.1364/OE.20.022976 ↗
56. 10.1016/S0006-3495(97)78784-810.1016/S0006-3495(97)78784-8 ↗
57. 10.1097/IAE.000000000000006510.1097/IAE.0000000000000065 ↗
58. 10.1016/j.ajo.2019.02.03210.1016/j.ajo.2019.02.032 ↗
59. 10.1529/biophysj.106.09983810.1529/biophysj.106.099838 ↗
60. 10.1529/biophysj.108.13363710.1529/biophysj.108.133637 ↗
61. 10.1007/s11095-013-1146-910.1007/s11095-013-1146-9 ↗
62. 10.1038/ncomms1298210.1038/ncomms12982 ↗
63. 10.1021/acs.accounts.6b0004110.1021/acs.accounts.6b00041 ↗
64. 10.1017/S003358351500001310.1017/S0033583515000013 ↗
65. 10.1038/s41377-018-0048-310.1038/s41377-018-0048-3 ↗
66. 10.1016/0142-9612(93)90055-710.1016/0142-9612(93)90055-7 ↗